224 related articles for article (PubMed ID: 14735696)
1. Bryostatin-1: a novel PKC inhibitor in clinical development.
Kortmansky J; Schwartz GK
Cancer Invest; 2003; 21(6):924-36. PubMed ID: 14735696
[TBL] [Abstract][Full Text] [Related]
2. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
3. The clinical development of the bryostatins.
Clamp A; Jayson GC
Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
[TBL] [Abstract][Full Text] [Related]
4. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
5. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells.
Stanwell C; Gescher A; Bradshaw TD; Pettit GR
Int J Cancer; 1994 Feb; 56(4):585-92. PubMed ID: 8112895
[TBL] [Abstract][Full Text] [Related]
6. Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells.
Rao AS; Freemerman AJ; Jarvis WD; Chelliah J; Bear HD; Mikkelsen R; Grant S
Leukemia; 1996 Jul; 10(7):1150-8. PubMed ID: 8683995
[TBL] [Abstract][Full Text] [Related]
7. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase calpha.
Gschwend JE; Fair WR; Powell CT
Mol Pharmacol; 2000 Jun; 57(6):1224-34. PubMed ID: 10825394
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Wang S; Wang Z; Grant S
Mol Pharmacol; 2003 Jan; 63(1):232-42. PubMed ID: 12488556
[TBL] [Abstract][Full Text] [Related]
11. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
Thomas A; Pepper C; Hoy T; Bentley P
Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
[TBL] [Abstract][Full Text] [Related]
13. Biological activity of 26-succinylbryostatin 1.
Bignami GS; Wagner F; Grothaus PG; Rustagi P; Davis DE; Kraft AS
Biochim Biophys Acta; 1996 Jul; 1312(3):197-206. PubMed ID: 8703988
[TBL] [Abstract][Full Text] [Related]
14. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
15. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
17. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.
Chelliah J; Freemerman AJ; Wu-Pong S; Jarvis WD; Grant S
Biochem Pharmacol; 1997 Sep; 54(5):563-73. PubMed ID: 9337072
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C-alpha but not protein kinase C-epsilon is differentially down-regulated by bryostatin 1 and tetradecanoyl phorbol 13-acetate in SH-SY5Y human neuroblastoma cells.
Jalava A; Lintunen M; Heikkilä J
Biochem Biophys Res Commun; 1993 Mar; 191(2):472-8. PubMed ID: 8461005
[TBL] [Abstract][Full Text] [Related]
20. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Jarvis WD; Povirk LF; Turner AJ; Traylor RS; Gewirtz DA; Pettit GR; Grant S
Biochem Pharmacol; 1994 Mar; 47(5):839-52. PubMed ID: 8135859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
